Evidence map›Paper›PMID 39158638›Full record

ArticleAnnals of surgical oncology2024

Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.

Kendra M Parrish, Samantha M Thomas, Sara B Cartwright, Astrid Botty van den Bruele, Rebecca Zasloff, Gayle A DiLalla, Maggie L DiNome, Carolyn S Menendez, Laura H Rosenberger, Hannah E Woriax and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kendra M ParrishDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Samantha M ThomasDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
Sara B CartwrightDepartment of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Astrid Botty van den BrueleDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Rebecca ZasloffDuke University School of Medicine, Durham, NC, USA.
Gayle A DiLallaDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Maggie L DiNomeDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Carolyn S MenendezDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Laura H RosenbergerDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Hannah E WoriaxDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
E Shelley HwangDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Jennifer K PlichtaDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Akiko ChibaDepartment of Surgery, Duke University Medical Center, Durham, NC, USA. Akiko.chiba@duke.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described. We evaluated overall survival (OS) between IBC patients and non-IBC patients who achieved pCR.

methodsAdult females diagnosed in 2010-2018 with clinical prognostic stage III unilateral invasive breast cancer treated with neoadjuvant chemotherapy (NAC) followed by surgery were selected from the National Cancer Database. Unadjusted OS from surgery was estimated using the Kaplan-Meier method, and log-rank tests were used to compare groups. Cox proportional hazard models were used to estimate the association of study groups with OS after adjustment for available covariates.

resultsThe study included 38,390 patients; n = 4600 (12.0%) IBC and n = 33,790 (88.0%) non-IBC. Overall pCR rates were lower for IBC compared with non-IBC (20.7% vs. 23.3%; p < 0.001). Among those achieving pCR, 5-year mortality was higher for IBC patients (16.4%, 95% confidence interval [CI] 13.9-19.1%) versus non-IBC patients (9.1%, 95% CI 8.4-9.8%; log-rank p < 0.001). Among all patients achieving pCR, IBC remained associated with worse OS compared with non-IBC (hazard ratio 1.48, 95% CI 1.19-1.85; p < 0.001).

conclusionWe found a lower pCR rate and worse OS in IBC patients compared with non-IBC stage III patients. Despite effective systemic therapies, achieving a pCR for IBC patients may not carry the same prognostic impact compared with non-IBC stage III patients.

Indexed as

Databases, FactualInflammatory Breast NeoplasmsNeoadjuvant TherapyAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansMastectomyMiddle AgedNeoplasm StagingPathologic Complete ResponsePrognosisRetrospective StudiesSurvival RateIBCInflammatory breast cancerNon-inflammatory breast cancerOverall survivalPathologic complete responsepCRStage III breast cancer

Identifiers

PMID39158638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.